R&D News | pharmaphorum

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

News

Biomarker study raises hope of better depression therapies

Researchers may have identified imaging-based biomarkers that could be used to identify different subtypes of major depressive disorder (MDD) and potentially lead to the d

News

Gates Foundation, Wellcome put $550m behind new TB jab

A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t

News

Sanofi sets out plan to lead the RSV vaccine market

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

News

Flywheel spins up $54m funding for its medical AI platform

Flywheel has raised $54 million in a new funding round that will be used to develop its platform to apply artificial intelligence to the interpretation of medical imaging

Eiger wields axe as FDA sets high bar for hepatitis drug

Biomarker study raises hope of better depression therapies

Gates Foundation, Wellcome put $550m behind new TB jab

Sanofi sets out plan to lead the RSV vaccine market

AbbVie, Genmab eye label expansion for Epkinly

Flywheel spins up $54m funding for its medical AI platform

AZ will invest £300m in UK, says PM Keir Starmer

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks